LLLatasha Ludwig

Latasha Ludwig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Latasha Ludwig has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intra-tumoral adipocytes in canine extramedullary plasma cell tumors

    by Agustín Rebollada-Merino, Latasha Ludwig

    Canine extramedullary plasma cell tumors (cePCTs) are common integumentary round-cell tumors. The presence of adipocytes among round cells, which is thought to be the result of trapping of subcutaneous adipocytes, is reported as a helpful diagnostic feature to distinguish cePCTs from other round-cell tumors in the skin. Here, we report our retrospective analysis of the prevalence, extent, and distribution of adipocytes in cePCTs from a single institution. We found adipocytes in 73 of 265 (27.5%) cePCT cases diagnosed from 2020–2024, suggesting that intra-tumoral adipocytes are a frequent histologic feature in cutaneous cePCTs. We found that 1–96% of the mass was composed of adipocytes, as quantified on whole-slide images. Of the cePCTs with adipocytes, 27 (37%) cases did not have significant involvement of the subcutis. Adipocyte-containing cePCTs were more frequent in our case series than were amyloid-producing cePCTs (19; 7%). A subset of 9 cases had limited involvement of the subcutis. The proportion of intra-tumoral adipocytes was far greater (>10%) than would be expected for simple entrapment of subcutaneous adipocytes, suggesting the promotion of proliferation of mature adipocytes by neoplastic cells.

  • Sex steroids in animals absent gonads: A case series

    by A.J. Conley, M.K. Keel, T. Raudsepp, M.N. Mendoza Cernac, R.J. Auchus, D.K. Lee, L.A. Ludwig, N.J. Place

  • Recognition and reporting of histologic features in canine integumentary mast cell tumors: An assessment of interpathologist agreement

    by Christopher P. Champion, Donald J. Meuten, Daniel R. Rissi, Aline Rodrigues-Hoffmann, Laetitia J. Tatiersky, Andrew D. Miller, Renée Laufer-Amorim, Ilaria Porcellato, W. Shane Sills, Emily Rätsep, et al.

    Canine integumentary mast cell tumors (CIMCTs) are common, and their clinical behavior can vary significantly. In an attempt to predict their biological behavior, veterinary pathologists utilize grading systems and assess specific histologic features, which are thought to carry prognostic significance. Assessment of interpathologist agreement with CIMCT grading systems has been investigated. However, for most individual histologic features that form the basis of these grading systems, there has been no investigation into how consistently they can be recognized and reported. This study evaluated the interpathologist agreement for morphologic diagnosis (ie, cutaneous vs subcutaneous mast cell tumors) and 31 histologic features commonly evaluated in CIMCTs by developing 2 surveys, without (survey 1) and with (survey 2) written definitions. Twenty-three veterinary anatomic pathologists located in 8 countries completed the surveys, which included 20 CIMCTs. Interpathologist agreement was calculated for each feature using Krippendorff’s alpha values (α). The degree of agreement for morphologic diagnosis was moderate (α = 0.452) and substantial (α = 0.611) in surveys 1 and 2, respectively. In both surveys, there was suboptimal (α < 0.400) agreement among pathologists in evaluating most histologic features (21/31 in survey 1; 20/31 in survey 2). Ulceration, tumor depth and width, and deep histologic tumor-free distance had the best agreement (range = 0.597–0.929) in both surveys. The features with the worst agreement (α ≤ 0.100) in both surveys were cytoplasmic granularity, degree of demarcation, degree of infiltration, chromatin pattern, nucleolar number, and nucleolar prominence. Written definitions did not categorically change interpathologist agreement for most (24/31) histologic features.


  • Generalized ataxia in a 6-year-old Goldendoodle

    by Tayla A. Regenbaum, Christine M. Senneca, Amanda R. Taylor, Latasha Ludwig

  • Open Access

    RT-qPCR normalization strategies for microRNA expression in cancer datasets

    by Heather Treleaven, Latasha Ludwig, Alicia Viloria-Petit, R. Darren Wood, R. Ayesha Ali, Geoffrey A. Wood

    Background and ObjectiveMicroRNAs (miRNAs) are a class of molecules with strong potential as diagnostic and prognostic markers for many cancers. This is due to their widespread expression in bodily fluids and tissues, and involvement in disease pathway signalling. The lack of consensus in normalizing miRNA expression data makes it difficult to compare results between studies. The goal of this study was to compare commonly used normalization protocols in different cancers and sample types to determine if the best choice is consistent across cancer and sample types, or specific to the cancer/sample type.MethodsThis study uses three previously generated RT-qPCR miRNA expression datasets representing two different types of cancer, and three biological sample types. Two commonly used endogenous control selection algorithms as well as other less optimal methods were used to test and compare normalization protocols across datasets.ResultsNormFinder and GeNorm both provided good reductions in variation, but NormFinder had a larger reduction in technical variation across all three datasets. Less optimal normalizers often introduced additional variation or had inconsistent effects.ConclusionThis work highlights the significance of proper endogenous control selection and the importance of using computational algorithms correctly. Given the better reduction in variation normalization by endogenous controls, specifically using the NormFinder algorithm, it is the recommended method for RT-qPCR miRNA expression normalization.

  • Top Cited Papers
    Open Access

    The oncogenome of the domestic cat

    by Bailey A. Francis, Latasha Ludwig, Chang He, Melanie Dobromylskyj, Christof A. Bertram, Heike Aupperle-Lellbach, Hannah Wong, Aiden P. Foster, Mark J. Arends, Alejandro Suárez-Bonnet, et al.

    Cancer is a common cause of morbidity and mortality in domestic cats. Because the mutational landscape of domestic cat tumors remains uncharacterized, we performed targeted sequencing of 493 feline tumor–normal tissue pairs from 13 tumor types, focusing on the feline orthologs of ~1000 human cancer genes. TP53 was the most frequently mutated gene, and the most recurrent copy number alterations were loss of PTEN or FAS or gain of MYC . By identifying 31 driver genes, mutational signatures, viral sequences, and tumor-predisposing germline variants, our study provides insight into the domestic cat oncogenome. We demonstrate key similarities with the human oncogenome, confirming the cat as a valuable model for comparative studies, and identify potentially actionable mutations, aligning with a “One Medicine” approach.


  • Open Access

    Differential expression of miRNAs in primary canine appendicular osteosarcoma tissue and pulmonary metastases

    by Latasha Ludwig, Heather Treleaven, Roger Moorehead, Robert A. Foster, R. Ayesha Ali, R. Darren Wood, Geoffrey A. Wood

    Canine appendicular osteosarcoma (OSA) is a highly metastatic tumor in dogs. Mortality due to metastatic disease is common and frequently occurs within 1 year of diagnosis despite standard-of-care treatment. Treatment includes amputation for palliation and chemotherapy for metastatic disease. Current histologic grading schemes and biomarkers are poor at predicting clinical outcome. Novel prognostic and therapeutic markers are required to improve patient care. MicroRNAs (miRNAs) are small molecules expressed by all cells and released into bodily fluids. Studies in human and canine OSA cell lines, tissues from the primary site, and blood have demonstrated the role of miRNAs in metastatic progression of OSA and its prognostication. We sought to investigate the miRNA profile of primary OSA tissue and compare it to pulmonary metastases and normal lung tissue by real-time quantitative polymerase chain reaction (PCR). Multiple miRNA and multiple variable models were investigated in primary OSA tissue to predict clinical outcome. Thirteen miRNAs had similar expression between primary and metastatic OSA but were different from normal lung tissue. MiR-9-5p, miR-196a-5p, and miR-196b were expressed in metastatic OSA but lacked expression in almost all normal lung samples. In multiple variable models for overall survival and disease-free interval, only miRNAs were selected as significant variables. This study found miRNAs that are nearly exclusively expressed in metastatic pulmonary OSA and could serve as novel therapeutic targets. MiRNAs were also found to be important prognostic biomarkers in tissue and improved prognostic ability as miRNA signatures.

  • Open Access

    Classification and Prognostication of B‐Cell and T‐Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs

    by Latasha Ludwig, Heather Treleaven, Roger Moorehead, Robert A. Foster, R. Darren Wood, R. Ayesha Ali, Geoffrey A. Wood

    Canine multicentric lymphoma is a common malignancy in dogs. It often responds well to initial chemotherapy but frequently relapses and has a poor response to subsequent treatment. B‐cell (BCL) and T‐cell (TCL) lymphomas differ in both their prognoses and chemotherapeutic treatment protocols. Currently, immunophenotyping can be costly and can only be performed on specific high‐quality samples. MicroRNAs (miRNAs) are small molecules present in blood and tissues and are dysregulated in both human and canine lymphoma. We investigated 59 miRNAs by RT‐qPCR to establish a serum miRNA profile in dogs with B‐cell and T‐cell multicentric lymphoma. Multiple miRNA pruned decision tree models were used to classify BCL and TCL cases from each other and controls, and to predict prognosis in BCL cases receiving standard CHOP chemotherapy. Six individual miRNAs were differentially expressed in serum between BCL and controls, and three were differentially expressed between BCL and TCL. A three‐miRNA model (miR‐155‐5p, miR‐1 and miR‐181b) could differentiate between BCL, TCL and control samples with an accuracy of 83.02%. A three‐miRNA model (miR‐125b‐5p, miR‐350 and let‐7b‐5p) in BCL samples separated the cases into four groups with hazard ratios ranging from 0.44 to 3.5 for overall survival. This study established a serum miRNA profile for both BCL and TCL and demonstrated the utility of multiple serum miRNA models to assist in the diagnosis of lymphoma and BCL prognostication.


  • Open Access

    MicroRNAs in serum and tissue can differentiate splenic hemangiosarcoma from other splenic masses in dogs

    by Latasha Ludwig, Heather Treleaven, Arlene Khachadoorian, Brigitte Degasperi, Ingrid Walter, Deirdre Stuart, Robert A. Foster, Robert Darren Wood, R. Ayesha Ali, Geoffrey A. Wood

    Splenic masses are common in dogs and vary dramatically in their clinical behavior. Clinically, and even with histology, it can be challenging to differentiate between benign and malignant splenic masses. Hemangiosarcoma (HSA), the most common malignancy of the spleen, is a very aggressive tumor with a poor prognosis. We hypothesize that microRNAs (miRNAs) in mass tissue and serum can differentiate between HSA and other splenic masses. Fifty-nine miRNAs were investigated by reverse-transcription followed by real-time quantitative polymerase chain reaction (RT-qPCR) in serum and/or tissue from dogs with HSAs (serum n = 24 and tissue n = 17; postsplenectomy serum n = 11), lymphomas (serum n = 8 and tissue n = 11), nonangiomatous nonlymphomatous sarcomas (serum n = 6 and tissue n = 10), histiocytic sarcomas (tissue n = 4), benign splenic masses (myelolipomas, nodular hyperplasia, and hematomas; total serum n = 21 and total tissue n = 35), and normal dogs (serum n = 14 and tissue n = 7). Numerous miRNAs were differentially expressed in serum and tissue of HSA cases compared to those with other splenic masses or normal spleens. In serum, our 5-miRNA model (miR-135a-5p, miR-10a, miR-450b, miR-152-3p, and miR-126-5p) accurately classified 100% (24/24) of dogs with HSA from normal dogs and those with a benign splenic mass (recall = 1 for HSA). The overall accuracy of the model was 86%. In HSA and benign splenic mass tissues, our 3-miRNA model (miR-126-5p, miR-502-3p, and miR-452-5p) accurately classified 96% of the cases. This study demonstrates the utility of miRNA models in serum and tissue for screening and diagnosis of HSA in dogs. Future studies include the evaluation of prospective and prediagnosis serum samples.